Nutriband CEO Publishes Letter to Shareholders

About this update from Nutriband Inc.

[{"type":"image","alt":"Nutriband Inc.","displaySize":"","headline":null,"caption":"Nutriband Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/e1fe1a06910d514b950ca827bdf3c344"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.H3TZ93yLU_ZLTp_tQ2eWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e1fe1a06910d514b950ca827bdf3c344","width":300,"height":82}},"lazy":false},{"type":"text","content":"ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The full text of the letter is below.","length":309,"tagName":"p"},{"type":"text","content":"Dear Shareholders,","length":18,"tagName":"p"},{"type":"text","content":"As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the beginning and now the many more who have joined our common goal along the way.","length":356,"tagName":"p"},{"type":"text","content":"This goal is to change the world for the better by creating technology designed to improve the safety standard of easily abused transdermal drugs while simultaneously focusing on making these safer treatments available to patients who require them.","length":248,"tagName":"p"},{"type":"text","content":"Some key points from 2025","length":25,"tagName":"p"},{"type":"text","content":"Strategic focus and Shareholder Value","length":37,"tagName":"p"},{"type":"text","content":"Shareholder value has always been and still is a core focus for us as a company and this has been evident through our reluctance to raise capital in the open market that may introduce additional warrants or unfavorable capital structures that could potentially mute our ability to grow in value. This has been evident in our recent announcement that we have agreed to sell 90% of our Pocono subsidiary for $5M USD to EarthVision Bio. This transaction should add $5M to our bottom line with no dilution to shareholders and we w...

More updates from Nutriband Inc.